Anticoagulation Strategies in Atrial Fibrillation

被引:4
作者
Menezes, Arthur R. [1 ]
Artham, Surya [1 ]
Lavie, Carl J. [1 ,2 ]
Khatib, Sammy [1 ]
机构
[1] Univ Queensland, Sch Med, Ochsner Clin Sch, Dept Cardiovasc Dis,John Ochsner Heart & Vasc Ins, New Orleans, LA USA
[2] Pennington Biomed Res Ctr, Dept Prevent Med, Baton Rouge, LA USA
关键词
Atrial fibrillation; Stroke; Antithrombotic therapy; Warfarin; SHORT-TERM ANTICOAGULATION; DUAL-ANTIPLATELET THERAPY; STROKE PREVENTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ELECTRICAL CARDIOVERSION; ANTITHROMBOTIC THERAPY; RISK STRATIFICATION; PREDICTING STROKE; FACTOR XA; THROMBOEMBOLIC EVENTS;
D O I
10.3909/ricm0616
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is a major risk factor for stroke and systemic embolization, particularly in the elderly. Approximately 2.3 million adults in the United States have AF, and it is projected that this number will increase to approximately 5.6 million individuals by the year 2050, with over 50% aged 80 years or older. Vitamin K antagonists are currently the most widely accepted means of stroke prevention in patients with AF; unfortunately, this method of treatment is not a feasible option for many patients for numerous reasons. This article examines and compares the various newer therapeutic agents that have either been approved by the US Food and Drug Administration or are still in various stages of clinical testing, and provides an overview of established antithrombotic therapies. We also discuss the role of anticoagulation in the setting of cardioversion in patients with AF. (C) 2012 MedReviews(R), LLC
引用
收藏
页码:E1 / E13
页数:13
相关论文
共 82 条
[11]   PATHOGENESIS OF ANTERIOR CIRCULATION STROKE IN PATIENTS WITH NONVALVULAR ATRIAL-FIBRILLATION - THE LAUSANNE-STROKE-REGISTRY [J].
BOGOUSSLAVSKY, J ;
VANMELLE, G ;
REGLI, F ;
KAPPENBERGER, L .
NEUROLOGY, 1990, 40 (07) :1046-1050
[12]  
Bousser MG, 2008, LANCET, V371, P315, DOI 10.1016/S0140-6736(08)60168-3
[13]  
Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/europace/euq350, 10.1093/eurheartj/ehq278]
[14]   Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial [J].
Connolly, S. ;
Pogue, J. ;
Hart, R. ;
Pfeffer, M. ;
Hohnloser, S. ;
Chrolavicius, S. ;
Yusuf, S. .
LANCET, 2006, 367 (9526) :1903-1912
[15]   Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation [J].
Connolly, S. J. ;
Yusuf, S. ;
Camm, J. ;
Chrolavicius, S. ;
Commerford, P. ;
Flather, M. ;
Hart, R. G. ;
Hohnloser, S. H. ;
Joyner, C. ;
Pfeffer, M. ;
Gaudin, C. ;
Blumenthal, M. ;
Marchese, C. ;
Pogue, J. ;
Hart, R. ;
Hohnloser, S. ;
Anand, I. ;
Arthur, H. ;
Avezum, A. ;
Budaj, A. ;
Ceremuzynski, L. ;
De Caterina, R. ;
Diaz, R. ;
Dorian, P. ;
Flaker, G. ;
Fox, K. A. A. ;
Franzosi, M. G. ;
Goldhaber, S. ;
Golitsyn, S. ;
Granger, C. ;
Halon, D. ;
Hermosillo, A. ;
Hunt, D. ;
Jansky, P. ;
Karatzas, N. ;
Keltai, M. ;
Kozan, O. ;
Lanas, F. ;
Lau, P. ;
Le Heuzey, J. Y. ;
Lewis, B. S. ;
Morais, J. ;
Morillo, C. ;
Paolasso, E. ;
Peters, R. J. ;
Pfisterer, M. ;
Piegas, L. ;
Pipilis, A. ;
Sitkei, E. ;
Swedberg, K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20) :2066-2078
[16]   CANADIAN ATRIAL-FIBRILLATION ANTICOAGULATION (CAFA) STUDY [J].
CONNOLLY, SJ ;
LAUPACIS, A ;
GENT, M ;
ROBERTS, RS ;
CAIRNS, JA ;
JOYNER, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (02) :349-355
[17]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[18]   The current role of anticoagulants in cardiovascular medicine [J].
De Caterina, Raffaele .
JOURNAL OF CARDIOVASCULAR MEDICINE, 2009, 10 (08) :595-604
[19]   Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment [J].
Eikelboom, John W. ;
O'Donnell, Martin ;
Yusuf, Salim ;
Diaz, Rafael ;
Flaker, Greg ;
Hart, Robert ;
Hohnloser, Stefan ;
Joyner, Campbell ;
Lawrence, Jack ;
Pais, Prem ;
Pogue, Janice ;
Synhorst, David ;
Connolly, Stuart J. .
AMERICAN HEART JOURNAL, 2010, 159 (03) :348-U38
[20]  
European Atrial Fibrillation Trial, 1993, LANCET, V342, P1255